Also, based on its in vitro activity to block the interaction between CTLA-4 and B7 ligand [14], our data suggest that the anti-tumor efficacy of half-life extended H11 would be attributed to inhibition of the interaction between CTLA-4 and its ligands. The gene discussed is CD80; the disease is neoplasm.